Drug intelligence / Profile preview

MH-003

Development stage: Preclinical
Lead developer: Mariposa Health

Overview

MH-003 is a preclinical immune modulator developed by Mariposa Health for the treatment of Staphylococcus aureus infections. It was part of Mariposa Health's pipeline that Genesis Research and Development Corporation sought to acquire in a proposed merger in 2010, which was later terminated.

Beyond the preview

Go deeper on MH-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MH-003.

Explore the full profile